{
  "docId": "019de073-7a8f-7069-abd7-4f5a253312a5",
  "docSlug": "7534f8dddd85d538a9efc95a5aebf002",
  "documentTitle": "Aquestive Therapeutics | Results Presentation Deck | 14 slides",
  "authorId": "aquestive-therapeutics",
  "authorName": "Aquestive Therapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 8,
  "pageCount": 14,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "Box plot showing baseline adjusted epinephrine Tmax.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7a8f-7069-abd7-4f5a253312a5/8",
  "deckHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5",
  "deckJsonHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5.json",
  "deckAnchorHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.08,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Baseline Adjusted Epinephrine Tmax EPIPHAST II",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1e36a2e-c044-468d-ae39-6edde45f31fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.54,
        "y": 0.7
      },
      "kind": "legend",
      "text": "Fastest Median Tmax",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80969f13-9b21-4f6d-9d40-0cf6f0fbe312",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "list",
      "text": "AQST-109 showed a shorter median Tmax than both 0.3 mg IM and 0.3 mg EpiPen. Range of Tmax values across study is consistent with EpiPen. Both EpiPen and AQST-109 provide faster median Tmax values than 0.3 mg IM",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30328c52-d61f-4573-a389-dcaf4562cf5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.19
      },
      "kind": "title",
      "text": "EPIPHAST II: Time to Maximum Concentration (Tmax)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67055462-5461-430b-9d1f-56aec2420360",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "65bff4a3-42c7-4ff6-98e6-7c0bd0e948b3",
      "evidence": "The slide presents information in a list format with bullet points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 3,
      "beatId": "fd64535f-8805-4be0-ab9c-f0396589752f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document provides relief through presentation of EPIPHAST II trial results, including key takeaways and data, on slides 3-13",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b6791be9-182b-48c3-8ddb-65cec4fe9e39",
      "evidence": "The document implies the cost of inaction through presentation of rapid epinephrine delivery and trial results",
      "position": 0,
      "objective": "What is the cost of not using Aquestive Therapeutics' epinephrine product?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}